Accelerating innovation in medicine and healthcare
Addressing healthcare’s biggest challenges demands new thinking; innovative approaches that place the best minds in a resource-rich environment to push the boundaries of discovery—thus helping to alter the course of human health for the benefit of people everywhere.
Innovation Statistics
100
In 2024, Dartmouth was designated one of the top 100 patent-producing universities worldwide.
140
entrepreneurially minded faculty and students have been supported by the Dartmouth Innovation Accelerator for Cancer.
#1
The Center for Technology and Behavioral Health is the nation's only NIH-funded Center of Excellence in digital therapeutics.
Innovation Testimonial
Because of our size and scale, we have the ability to spur innovation at the intersections of disciplines and amplify this combination in service to society. It is in that space between where there is ample ground for new approaches and invention. That’s the Dartmouth way.
Dartmouth Innovation in Medicine & Healthcare Event Series
Through a combination of flagship and satellite events held in select cities and virtually, this series invites attendees to learn and become a part of Dartmouth’s thriving ecosystem of innovation and discovery. By leveraging the unparalleled network of Dartmouth supporters, alumni, entrepreneurs, and friends, this series is fueling important discussions on the future of health and healthcare. We hope to see you at an upcoming event!
Delivering Behavioral Health Care to You, When You Need It Most
With behavioral health care in high demand, there are not enough trained clinical professionals to meet the need. That’s where the Center for Technology and Behavioral Health (CTBH) comes in. At CTBH, innovators and clinicians across disciplines are developing and evaluating digital technologies to bring personalized, science-based care to patients anytime, anywhere.
First Therapy Chatbot Trial Yields Mental Health Benefits
In the first-ever clinical trial of a generative AI-powered therapy chatbot, CTBH researchers found that the software resulted in significant improvements in participants’ symptoms. While AI-powered therapy is still in critical need of clinician oversight, these results show that it has the potential to provide real-time support for the many people who lack regular or immediate access to a mental-health professional. The results of this groundbreaking study were featured in The New York Times, Forbes, MIT Technology Review, and more.
Curious to Learn More?
To learn more about innovation at Dartmouth and find out how you can get involved, please contact:
Bethany Solomon
Assistant Vice President, Principal Gifts and Venture Philanthropy
Bethany.Solomon@dartmouth.edu
Investing in Healthcare Delivery Innovation for Maximum Impact
A joint venture between Dartmouth Health and The Dartmouth Institute for Health Policy & Clinical Practice, The Richard and Susan Levy Health Care Delivery Incubator launched in 2020 to transform the delivery of healthcare. It serves as a shining example of how innovation can drive tangible impact for patients and their families—and begin to heal a healthcare system that has long been viewed as broken.
Lung Cancer Screening Rates Are Low. This Team Is Changing That.
A team at Dartmouth Health and the Geisel School of Medicine at Dartmouth has worked to destigmatize lung cancer screening and increase lung cancer screening rates for rural communities in New Hampshire and Vermont. The initiative, supported in part by the Levy Incubator, has already had a substantial impact on patients.
Backing entrepreneurs. Igniting discovery. Fueling hope.
The Dartmouth Innovation Accelerator for Cancer (DIAC) was launched in 2020 with a bold goal: bring the best cancer therapies to market, faster. Powered by an extensive and dedicated network of alumni from across Dartmouth, DIAC exists to quicken the pace of cancer research, nurture innovative discoveries through the development pipeline, and offer hope to patients and families.
Cancer's Most Wanted Target: The Undruggable MYC
For decades, cancer researchers have been stymied by an elusive challenge: a gene that fuels unchecked cell growth. Myelocytomatosis oncogene (known as MYC) plays a role in most deadly tumors. Yet efforts to develop drugs to rein it in have fallen short. Now, two Dartmouth scientists may have finally cracked the “MYC problem” in cancer. With support in part from DIAC, the pair has devised an innovative new strategy to target this “undruggable” gene.
A 'One Dartmouth' Approach to Accelerating Innovation in Medicine and Healthcare
Our ability to advance innovative approaches to science and medicine is built upon a One Dartmouth foundation: the notion that various corners of Dartmouth and Dartmouth Health—from boundary-pushing institutes and entrepreneurially minded centers to unparalleled professional schools and interdisciplinary academic departments—each have a critical and interconnected role to play in driving innovation and translating that innovation to impact.
Armed with this approach, Dartmouth can be greater than the sum of its parts.
